Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote biosimilar development and utilization.
Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability. HER2-positive breast cancer ...
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...
German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback